Literature DB >> 7650379

Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity.

R A Vescio1, J Cao, C H Hong, J C Lee, C H Wu, M Der Danielian, V Wu, R Newman, A K Lichtenstein, J R Berenson.   

Abstract

The lg VH region sequence in 48 patients with multiple myeloma (MM) was analyzed to characterize the malignant cell of origin. The sequences were obtained after amplification of bone marrow cDNA by using VH family-specific and CH primers, then compared with either directly sequenced patient germ-line or published VH gen sequences to assay for somatic mutation. Because somatic hypermutation of the VH gene occurs late in B cell development, its presence has been helpful in determining the cell of origin in other B cell malignancies. Overall, a median of 8.2% of the nucleotides had evidence of substitution within each VH gene sequence (range=2.7% to 16.5%), which is more prevalent than in any other reported tumor type. Strong evidence of prior antigenic selection pressure was also evident. The ratio of nucleotide substitutions that resulted in amino acid replacement was significantly higher in the complementarity-determining region than in the framework region (3.25 vs 1.56, respectively; p < 0.00005). No VH gene intraclonal diversity was noted, despite sequencing multiple clones (3-16) from each patient, nor was there evidence of further VH gene somatic mutation over the course of three patients' disease. These findings strongly imply that the malignant clone in MM evolves from a cell late in B cell development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650379

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.

Authors:  Roshini S Abraham; Michelle K Manske; Neta S Zuckerman; Abhishek Sohni; Hanna Edelman; Gitit Shahaf; Michael M Timm; Angela Dispenzieri; Morie A Gertz; Ramit Mehr
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

Review 3.  Cancer stem cells in multiple myeloma.

Authors:  Nilanjan Ghosh; William Matsui
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

Review 4.  Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells.

Authors:  H K Müller-Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 5.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

6.  Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.

Authors:  Joshua Kellner; Caroline Wallace; Bei Liu; Zihai Li
Journal:  JCI Insight       Date:  2019-04-04

Review 7.  Somatic hypermutation and B-cell lymphoma.

Authors:  D Dunn-Walters; C Thiede; B Alpen; J Spencer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

Review 8.  Multiple myeloma-initiating cells.

Authors:  Naoki Hosen
Journal:  Int J Hematol       Date:  2013-02-19       Impact factor: 2.490

Review 9.  Multiple myeloma cancer stem cells.

Authors:  Carol Ann Huff; William Matsui
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

10.  Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease.

Authors:  D Zhu; C van Arkel; C A King; S V Meirvenne; C de Greef; K Thielemans; J Radl; F K Stevenson
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.